
Novo Nordisk’s capital markets day transpires on Thursday, and the pharmaceutical firm has aired some key highlights ahead of the meeting, as announced in a stock notification.
The four main points on the agenda for the day include a focus on how Novo Nordisk can secure growth beyond semaglutide by ”building on core research capabilities and new technology platforms.”
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app